Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
Lung Cancer. 2013 Nov;82(2):358-61. doi: 10.1016/j.lungcan.2013.08.011. Epub 2013 Aug 18.
A Simplified Comorbidity Score (SCS) provided additional prognostic information to the established factors in patients with non-small cell lung cancer lung cancer. We undertook this analysis to test the prognostic value of the SCS in a population-based study.
Retrospective survey of all Victorians diagnosed with lung cancer in January-June 2003, identified from the Victorian Cancer Registry.
There were 921 patients, with data available for 841 (91.3%). Median age was 72 years (range 30-94) and 63.1% were male. A tissue diagnosis was made for 89.9%, of which 86.6% were non-small cell (NSCLC), and 13.4% small cell carcinoma (SCLC). Comorbidities on which the SCS is based were distributed: cardiovascular 54.6%; respiratory 38.9%; neoplastic 19.9%; renal 4.6%; diabetes 11.7%; alcoholism 5.5%; and tobacco 83.1%. In patients with NSCLC, higher SCS score (>9) was associated with increasing stage, ECOG performance status, male sex, increasing age, tobacco consumption and not receiving treatment. Using Cox regression, survival was analysed by SCS score after adjusting for the effect of age, sex, cell type (NSCLC, SCLC, no histology), ECOG performance status and stage for all patients and then restricted to NSCLC. As a continuous or dichotomous (≤ or >9) variable, SCS was not a significant prognostic factor for all patients or when restricted to NSCLC.
In this retrospective analysis of population based registry patients, SCS did not provide additional prognostic information in patients with lung cancer. ECOG performance status may be a substitute for the effect of comorbidity.
简化合并症评分（SCS）为非小细胞肺癌患者提供了除既定因素之外的额外预后信息。我们进行这项分析是为了在基于人群的研究中测试 SCS 的预后价值。
回顾性调查 2003 年 1 月至 6 月期间维多利亚癌症登记处诊断的所有肺癌患者。
共 921 例患者，其中 841 例（91.3%）有数据。中位年龄为 72 岁（范围 30-94 岁），63.1%为男性。89.9%的患者进行了组织学诊断，其中 86.6%为非小细胞癌（NSCLC），13.4%为小细胞癌（SCLC）。SCS 所依据的合并症分布如下：心血管疾病 54.6%；呼吸系统疾病 38.9%；肿瘤疾病 19.9%；肾脏疾病 4.6%；糖尿病 11.7%；酒精中毒 5.5%；烟草 83.1%。在 NSCLC 患者中，较高的 SCS 评分（>9）与疾病分期较高、ECOG 体能状态、男性、年龄增加、烟草使用和未接受治疗相关。在调整年龄、性别、细胞类型（NSCLC、SCLC、无组织学）、ECOG 体能状态和分期对所有患者进行生存分析后，使用 Cox 回归分析 SCS 评分的生存情况，然后将分析限制在 NSCLC 患者中。作为连续或二分类（≤或>9）变量，SCS 不是所有患者或仅限于 NSCLC 患者的显著预后因素。
在这项基于人群的登记患者回顾性分析中，SCS 未为肺癌患者提供额外的预后信息。ECOG 体能状态可能是合并症影响的替代指标。
